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Introduction: Alzheimer’s disease (AD) is characterized by cerebral glucose
hypometabolism. Hypometabolism may be partly due to reduced glucose transport
at the blood-brain barrier (BBB) and across astrocytic and neuronal cell membranes.
Glucose transporters (GLUTs) are integral membrane proteins responsible for moving
glucose from the bloodstream to parenchymal cells where it is metabolized, and
evidence indicates vascular and non-vascular GLUTs are altered in AD brains, a process
which could starve the brain of glucose and accelerate cognitive decline. Here we review
the literature on glucose transport alterations in AD from human and rodent studies.
Methods: Literature published between 1st January 1946 and 1st November 2020
within EMBASE and MEDLINE databases was searched for the terms “glucose
transporters” AND “Alzheimer’s disease”. Human and rodent studies were included while
reviews, letters, and in-vitro studies were excluded.
Results: Forty-three studies fitting the inclusion criteria were identified, covering human
(23 studies) and rodent (20 studies). Post-mortem studies showed consistent reductions
in GLUT1 and GLUT3 in the hippocampus and cortex of AD brains, areas of the brain
closely associated with AD pathology. Tracer studies in rodent models of AD and human
AD also exhibit reduced uptake of glucose and glucose-analogs into the brain, supporting
these findings. Longitudinal rodent studies clearly indicate that changes in GLUT1 and
GLUT3 only occur after amyloid-β pathology is present, and several studies indicate
amyloid-β itself may be responsible for GLUT changes. Furthermore, evidence from
human and rodent studies suggest GLUT depletion has severe effects on brain function.
A small number of studies show GLUT2 and GLUT12 are increased in AD. Anti-diabetic
medications improved glucose transport capacity in AD subjects.
Conclusions: GLUT1 and GLUT3 are reduced in hippocampal and cortical regions in
patients and rodent models of AD, andmay be caused by high levels of amyloid-β in these
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regions. GLUT3 reductions appear to precede the onset of clinical symptoms. GLUT2
and GLUT12 appear to increase and may have a compensatory role. Repurposing
anti-diabetic drugs tomodify glucose transport shows promising results in human studies
of AD.
Keywords: GLUT 3, GLUT 1, blood-brain barrier, glucose transporters, Alzheimer’s disease
INTRODUCTION
Background
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder
characterized by the presence of β-amyloid (Aβ) plaques and
neurofibrillary tangles (NFTs) (Grundke-Iqbal et al., 1986;
Scheltens et al., 2016). The majority of AD is sporadic, with <5%
being classified as genetic (Reitz et al., 2011). Several mechanisms
have been proposed for its pathophysiology. According to the
amyloid cascade hypothesis, the Aβ precursor protein (APP)
is abnormally cleaved, leading to an imbalance between Aβ
production and clearance, favoring the accumulation of Aβ. This,
in turn, forms clusters in the brain which induce oxidative stress,
leading to synaptic dysfunction, neuronal death, and subsequent
cerebral atrophy (Chételat et al., 2010). These clusters, called
oligomers, form fibrils, then beta-sheets and eventually develop
into plaques which are considered a hallmark of AD (Grundke-
Iqbal et al., 1986). While Aβ accumulation has a critical role in
AD, it is becoming increasingly recognized that brain Aβ burden
does not correlate with the severity of cognitive impairment
(Games et al., 1995; Price et al., 2009). Aβ accumulation
also occurs in aging individuals without cognitive impairment
(Castello and Soriano, 2014; Morris et al., 2014; Herrup, 2015),
indicating the limitations of the amyloid hypothesis (Kametani
and Hasegawa, 2018). The tau hypothesis conjectures that tau
is the main causative protein for AD (Kosik et al., 1986).
Tau is a protein normally associated with microtubules which
serve to stabilize tubulin assemblies. In AD, tau is abnormally
hyperphosphorylated and forms pathological inclusions known
as NFTs, which are widely identified in AD brains. Tau is
more strongly associated with cognitive impairment than Aβ
(Hanseeuw et al., 2019). However, attempts to stabilize cognitive
function through modification of Aβ and tau in the clinical
setting have been unsuccessful to date (Congdon and Sigurdsson,
2018; Yiannopoulou and Papageorgiou, 2020).
Hypometabolism in AD
In addition to Aβ and tau, AD is considered a metabolic disorder,
which relates to reduced cerebral glucose metabolism, brain
insulin resistance, and age-induced mitochondrial dysfunction
(Van Der Velpen et al., 2019). The conventional view is that
reduced brain metabolism is secondary to brain atrophy and
neuronal loss (Bokde et al., 2001). However, there is accumulating
evidence that hypometabolism occurs before the onset of brain
atrophy and clinical symptoms, indicating that changes in
metabolism may occur prior to reduced glucose demand by
tissues (De Leon et al., 2001; Jagust et al., 2006; Mosconi et al.,
2006, 2008, 2009; Masdeu, 2008).
Abnormal cerebral glucose metabolism was observed using
FDG-PET in 1983 by de Leon et al. (1983), who observed a
17–24% reduction in the regional cerebral metabolic rate of
glucose (CMRglu) in a cohort of 24 AD patients. This correlated
with a reduction in cognitive performance compared to age
matched controls. Later studies confirmed these results, building
support for regional declines in CMRglu as a hallmark of AD,
including in frontal white matter, caudate, thalamus, temporal,
and parietal regions (Small et al., 2000; Mosconi et al., 2004,
2007a). Masdeu (2008) examined seven pre-symptomatic, at-risk
subjects with familial AD using MRI and FDG-PET imaging.
Compared to seven matched healthy controls, the familial AD
subjects showed a reduction in glucose metabolism in most brain
regions examined, including the whole brain, right, and left
inferior parietal lobules, superior temporal gyrus, left entorhinal
cortex, posterior cingulate cortex, and hippocampus. De Leon
et al. (2001), Mosconi et al. (2008), and Jagust et al. (2006)
examined CMRglu in multiple brain regions of healthy elderly
individuals using FDG-PET and MRI scans to differentially
predict cognitive decline from normal aging. In all three studies,
reductions in glucose metabolism predicted cognitive decline in
those participants who went on to develop cognitive impairment
or a clinical diagnosis of AD.
In a longitudinal study, Mosconi et al. (2009) examined four
cognitively normal elderly subjects and three patients with mild
AD. Their pathological diagnosis was verified through post-
mortem studies 6 ± 3 years after the subjects’ last FDG-PET
scan. All participants who were cognitively intact at baseline
developed mild cognitive impairment (MCI) 2–7 years after
their baseline assessment. On post-mortem studies, two of these
subjects had definite AD, one had probable AD and the last
had pathological findings consistent with Parkinson’s disease
with mild AD-related pathology. In all four patients, CMRglu
was reduced in areas involving the hippocampus, up to 7 years
before their diagnosis of MCI. Follow up FDG-PET scans showed
progressive reductions in CMRglu with wider brain involvement
including the temporal and parietal lobes, and to varying degrees
the anterior and posterior cingulate regions. A more recent
study by Ou et al. (2019) examining 551 participants with AD
observed reduced metabolism as measured using FDG-PET as
an independent biomarker for AD. Their findings demonstrate
faster cognitive decline and brain atrophy in participants with
reduced metabolism.
Glucose Transport as the Rate-Limiting
Step in Glucose Metabolism
While these studies included a small number of participants, their
results suggest that hypometabolism precedes a clinical diagnosis
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TABLE 1 | GLUTs expressed in the central nervous system.
Protein (gene) References Insulin sensitive
(Yes/No)
Site expressed in the CNS
GLUT1 (SLC2A1) Kumari and Heese, 2010 No Endothelial cells (55 kDa isoforms), astrocytes (45 kDa
isoforms)
GLUT2 (SLC2A2) Kumari and Heese, 2010 No Astrocytes
GLUT3 (SLC2A3) Kumari and Heese, 2010 No Endothelial cells, astrocytes, hippocampal neurons
GLUT4 (SLC2A4) Leloup et al., 1996; Vannucci et al., 1998;
Reagan, 2002; Kumari and Heese, 2010
Yes Hypothalamic neurons, hippocampal neurons, cerebellar
neurons, sensorimotor cortex, pituitary
GLUT8 (SLC2A8) Kumari and Heese, 2010 Yes Hypothalamic neurons, hippocampal neurons
GLUT12 (SLC2A12) Zhang et al., 2014 (details extracted from
https://www.brainrnaseq.org)
Yes Cortical astrocytes
of AD. Glucose metabolism requires both delivery of glucose to
cells from the bloodstream, and phosphorylation by hexokinase
at the site of mitochondria. One possible explanation for early
changes to glucose metabolism observed via FDG-PET may be
due to abnormal delivery of glucose to the brain. Glucose is
a hydrophilic molecule and requires transporters to cross cell
membranes. Glucose uptake into the brain occurs predominantly
via the sodium-independent facilitative transporters GLUT1
and GLUT3, encoded by the SLC2A1 and SLC2A3 genes,
respectively. GLUT1 is responsible for glucose uptake across the
BBB endothelial cells, where the higher density isoforms are
located (55 kDa), and into astrocytes, where the lower density
isoforms are located (45 kDa). Glucose uptake into the brain
appears to correlate with the number of GLUT1 transporters at
the BBB (Zeller et al., 1997). Neurons do not express GLUT1
(Zlokovic, 2011). The main glucose transporter that facilitates
uptake of glucose into neurons is GLUT3, which is encoded
by the SLC2A3 gene. GLUT3 is also detected at lower levels
on astroglial and endothelial cells (Kumari and Heese, 2010;
Patching, 2017). Low levels of GLUT2, encoded by the SLC2A2
gene, are present on astrocytes (Magistretti and Pellerin, 1999;
Larrabee, 2002). Reduced supply of glucose to the brain via loss
of these major glucose transporters may lead to a brain glucose
deficit, halting metabolism and other processes dependent on
ATP production (Iadecola, 2015).
Several insulin-sensitive transporters are present in the
brain at low levels, including GLUT4, a transporter mainly
present in non-cerebral fat and muscle tissue, GLUT8, which
has been suggested to contribute toward glucose homeostasis
in hippocampal neurons (Piroli et al., 2002), and GLUT12,
a newly discovered glucose transporter found primarily in
insulin-sensitive tissues (Szablewski, 2017). The location of these
transporters within the central nervous system (CNS) and their
presence on different cell types are shown in Table 1, Figure 1.
Detailed descriptions of glucose transporters and their
respective functions are not described here—these aspects
have been reviewed extensively elsewhere by Szablewski
(2017) and Koepsell (2020). Szablewski (2017) also reviewed
glucose transporter alterations in AD with particular focus on
links between AD and insulin resistance, but a systematic
review of human and animal data was not performed.
Furthermore, Szablewski did not cover in detail results
from tracer studies of glucose uptake into the brain, the
effects of AD pathologies such as amyloid-β and tau on
GLUTs, the timing of effects, or how GLUT alterations
affect the brain. Here we perform a systematic review to
capture all human and rodent studies of glucose transport
alterations in AD to date and aim to evaluate the evidence
to support (i) which transporters are affected, if any, (ii) how
glucose uptake into the brain is altered, (iii) which brain
regions are most affected, (iv) when changes occur relative
to other AD pathologies, and (v) how GLUT changes affect
brain function.
METHODS
Literature published between 1st January 1946 and 1st
November 2020 was searched using the PubMed search
engine. Exploded headings were used for “glucose transporters”
and “Alzheimer’s disease” with the Boolean operator “AND.”
Searches were performed in EMBASE and MEDLINE databases
and duplicates were removed. Only studies investigating
cerebral glucose transporters were included. Titles and
abstracts were scanned to identify relevant papers and
articles, and those which did not clearly examine glucose
transport specific to Alzheimer’s disease were discussed
with the research team and excluded if not considered
relevant. Human and rodent studies (post-mortem and
in-vivo) were included and results are summarized in
Tables 2, 3. Reviews, letters and in-vitro studies were
excluded. Figure 2 shows the PRISMA flow chart detailing
the search results.
RESULTS
Twenty-three human studies and twenty rodent studies met the
inclusion criteria. The transporter GLUT1 was most commonly
investigated (n = 23), followed by GLUT3 (n = 13). A total of
10 human studies and 12 rodent studies observed reductions
in GLUT1 expression, primarily in cortical and hippocampal
regions. One study found increased GLUT1 expression. A total
of 5 human studies and 6 rodent studies found reductions to
GLUT3 expression. One study found no change, and one study
Frontiers in Neuroscience | www.frontiersin.org 3 May 2021 | Volume 15 | Article 626636
Kyrtata et al. Glucose Transport Alterations in AD
FIGURE 1 | A schematic diagram representing the expression of glucose transporters within CNS cells. Red: GLUT1 55 kDa isoform, pink: GLUT1 45 kDa isoform.
GLUT1 (Kumari and Heese, 2010), GLUT2 (Kumari and Heese, 2010), GLUT3 (Kumari and Heese, 2010), GLUT4 (Leloup et al., 1996; Vannucci et al., 1998; Reagan,
2002; Kumari and Heese, 2010), GLUT8 (Kumari and Heese, 2010), GLUT12 (Zhang et al., 2014) (details extracted from https://www.brainrnaseq.org on 19/04/2021).
found increased GLUT3 expression. There were fewer studies
investigating GLUT2 (n= 2, both showing increased expression),
GLUT4 (n = 6; no changes observed in 4 studies, one study
showing increased GLUT4), GLUT12 (n = 1 showing increased
expression), and GLUT14 (n = 1). Tracer-based methods were
used to measure glucose uptake into brain tissue in 9 studies. All
tracer studies except one reported reduced glucose uptake into
the brain with AD, although in rodent studies reduced uptake
was not observed until later stages of disease. A detailed review
of all studies is given below.
Evidence of Glucose Transporter
Alterations in AD From Post-Mortem
Human and Rodent Studies
Early work by Kalaria and Harik (1989) showed a significant
reduction in hexose transporters, primarily GLUTs, in the
neocortex and hippocampus of post-mortem AD brain tissue. In
a subsequent study, Harik (1992) showed a significant reduction
in the density of GLUT1 in the cerebral microvessels in the
AD brain compared to age-matched controls, with no change
in the density of GLUT1 in erythrocyte membranes. Simpson
et al. (1994) showed that AD patients display reduced density of
vascular and non-vascular forms of glucose transporters, GLUT1
and neuronal GLUT3. After correcting for synaptic loss, which
is a prominent feature of AD (Masliah et al., 1990, 1991; Terry
et al., 1991; Honer et al., 1992), the authors confirmed that
the reduction in GLUT density persisted. Similar results were
shown by Horwood and Davies (1994) who observed GLUT1
reductions in hippocampal tissue of the AD brain. Harik and
Kalaria (1991) observed a decrease of ∼50% in the density of
glucose transporters in cerebral microvessels of patients with AD.
They identified glucose transporters by reversible and irreversible
binding to the ligand [3H] cytochalasin B. The type of glucose
transporter identified using this method was not stated, however,
cytochalasin B is an inhibitor of glucose transport in erythrocytes
(May, 1988; Carruthers and Helgerson, 1991) and is likely to
reflect GLUT1 levels.
Mooradian et al. (1997) observed a reduction in GLUT1 in the
frontal and parietal cortex of AD brain, albeit with unchanged
GLUT1 mRNA concentrations. In a study of hippocampal
microvasculature, Burke et al. (2014) examined GLUT1 as a
marker of capillary density in post mortem brain tissue of
patients with AD, stroke, vascular dementia, and mixed-type
dementia. Contrary to previous studies, they observed increased
GLUT1 density in AD brain tissue compared to controls. By
contrast, a very recent study investigating white matter tissue
from the AD brain demonstrated collapsed string microvessels
along with loss of GLUT1 immunoreactivity in the white matter
of the frontal lobe compared to overlying cortex (Hase et al.,
2019).
Liu et al. (2009) studied AD patients with and without type-
2 diabetes mellitus (T2DM), and patients with T2DM alone.
They showed that GLUT1 was significantly reduced in AD
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Immunohistochemistry study of brain tissue obtained from the
frontal and temporal neocortex, hippocampus, putamen,
cerebellum, and cerebral microvessels in AD subjects and controls
to determine levels of hexose transporter (likely GLUT1, although
not specified).
Significant reduction in hexose expression (likely GLUT1)
transporter in brain microvessels, cerebral neocortex and
hippocampus of AD brain.
Kawai et al., 1990 Immunohistochemistry study of the relationship between Aβ
plaques, capillary density (collagen-4), and glucose transporters
(GLUT1).
Collagen-4 and GLUT1 expression was reduced within Aβ plaques
and increased in the immediate surroundings of Aβ plaques
relative to gray matter.
Harik and Kalaria,
1991
Immunohistochemistry study of GLUT1 in cerebral microvessels of
subjects with AD and age matched controls using irreversible
binding to the ligand [3H] cytochalasin B.
GLUT1 expression was decreased by ∼50% in cerebral
microvessels of patients with AD compared to age-matched
controls.
Harik, 1992 Immunohistochemistry study of GLUT1 in AD brain tissue and
controls.
Reduction in the expression of GLUT1 in the cerebral microvessels
in AD brain compared to age-matched controls, with no change in
the density of GLUT1 in the erythrocyte membranes.
Horwood and Davies,
1994
Immunohistochemistry study of AD brain tissue obtained from the
central part of the hippocampal formations (dentate gyrus, cornu
ammonis, and subicular complex) to determine levels of
microvascular GLUT1.
GLUT1 expression was significantly reduced in the microvessel
endothelium in hippocampi of AD subjects compared to controls.
Simpson et al., 1994 Immunoblotting study of brain tissue obtained from AD subjects
and controls.
Reduced glucose metabolism in the temporal and parietal regions
of AD subjects. Reduced expression of GLUT1 and GLUT3 in the
cerebral cortex of AD brains compared to controls, with greater
and more significant reductions in GLUT3.
Harr et al., 1995 Immunohistochemistry study of brain tissue obtained from the
dentate gyrus of AD subjects’ to determine levels of GLUT3.
Significant reduction (49.5%) in GLUT3 expression in the outer
portion of the molecular layer of the dentate gyrus in AD brains.
Mooradian et al., 1997 Western-blot study of GLUT1 in brain tissue from AD subjects and
controls.
GLUT1 expression was reduced in AD but GLUT1 mRNA
concentrations were not significantly different.
Liu et al., 2008 Western-blots and immune-dot-blot study of GLUT1-4 levels in
the frontal cortex of frozen human brain tissue in subjects with AD
and controls.
Decreased expression of GLUT1 and GLUT3 in AD brain tissue
which correlated to hyperphosphorylation of tau and neurofibrillary
tangle density. Downregulation of hypoxia-inducible factor 1
(HIF-1) in AD brain.
Liu et al., 2009 Western-blots and immune-dot-blot study of brain tissue obtained
by autopsy from AD patients, subjects who had T2DM and
subjects who had both AD and T2DM.
GLUT1 expression was significantly lower in AD brains.
GLUT2 expression was significantly higher in AD brain and brain of
subjects with both AD and T2DM.
GLUT3 expression was significantly lower in all three groups with
the lowest levels in T2DM brain.
O-GlcNAcylation of global proteins and tau was downregulated in
T2DM brain and AD brain.
Tau phosphorylation is higher in T2DM brain and AD brain.
Wang et al., 2012 A case-control study was performed in a Chinese population of
597 patients with AD and 605 healthy controls examining the role
of SLC2A14, the gene encoding GLUT14, in developing late-onset
AD. Results were stratified by ApoEε4-carrying status.
The rs10845990 polymorphism within the gene coding for
GLUT14 was significantly associated with late onset AD in
non-ApoEε4 allele carriers (p < 0.001).
Pujol-Gimenez et al.,
2014
Western blot study of brain tissue obtained from the frontal cortex
of AD subjects and age-matched controls measuring the
expression of GLUT12.
GLUT12 expression was significantly increased in AD compared to
age-matched controls.
Burke et al., 2014 Immunohistochemistry study of GLUT1 in patients with AD,
vascular dementia and patients who had suffered from stroke. The
cumulative vessel length and diameter of hippocampal
microvessels was measured using stereological spherical probe
software.
Increases in percentage per area were found in GLUT1 density in
AD cases in the:
• CA1 of the hippocampus compared with post-stroke non-
demented subjects (p = 0.011).
• CA1 of the hippocampus compared with post-stroke demented
subjects (p = 0.037).
• CA2 of the hippocampus compared to vascular dementia
subjects (p = 0.04).
• Entorhinal cortex compared with post-stroke non-demented
subjects (p = 0.004).
Post-stroke demented cases had significantly lower vascular
length than AD (p = 0.016). Post-stroke non-demented cases had
significantly lower vascular length compared with controls
(p = 0.015).
(Continued)
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TABLE 2 | Continued
References Methods Findings
Mullins et al., 2017 Immunohistochemistry study into the relationship between brain
insulin resistance and glucose transporter expression and the
propensity to develop plaques and NFT.
Regional expression of GLUT1 showed a negative correlation with
NFT density.
Regional expression of GLUT4 showed a positive correlation with
NFT density.
Areas with reduced insulin signaling proteins (including IRS-1)
showed higher NFT load.
An et al., 2018 LC-MS/MS study to measure GLUT1 and GLUT3 levels in brain
tissue obtained from the middle frontal gyrus of 14 participants
with AD, 14 controls, and 15 with asymptomatic AD (ASYMAD).
GLUT3 levels were lower in both AD and ASYMAD groups
compared to controls, before and after adjusting sex, age at death
and neuronal nuclear protein levels. Lower levels of GLUT3
correlated with the severity of both Aβ and NFT pathology.
Hase et al., 2019 Immunohistochemistry study of endothelial GLUT1. Microvascular
pathology, capillary width and densities were measured using
histopathological methods in the frontal lobe white matter across
several dementia types including 18 participants with AD.
Collapsed string microvessels along with loss of GLUT1
immunoreactivity was detected in AD frontal lobe white matter
compared to overlying cortex.
Friedland et al., 1989 Dynamic FDG-PET study in patients with probable Alzheimer’s
disease (AD) and healthy age-matched controls.
There was no significant difference in rate constants for glucose
transport (k1 and k2) or phosphorylation (k3).
Jagust et al., 1991 Dynamic FDG-PET study in six subjects with clinical criteria for
probable AD and normal controls.
Decrease in K1 in frontal and temporal cortex in AD subjects
compared to controls, minimal differences in occipital cortex and
white matter and decreased rCMRglc in all cortical regions.
Non-significant decrease in k3 in all brain regions of AD subjects.
Kimura and
Naganawa, 2005
Dynamic FDG-PET study in three subjects; a 45-year-old normal
subject, a 65-year-old subject with mild AD, and a 70-year-old
subject with severe AD.
Glucose transport was globally reduced in both AD cases
compared to the normal subject. Glucose phosphorylation was
diminished in gray matter of the severe case of AD, excluding the
sensory, motor, and visual cortices. In the mild case,
phosphorylation was reduced in the right parieto-temporal area.
Piert et al., 1996 Dynamic FDG-PET study in AD subjects and normal controls. Significant reductions in glucose transport (K1) and
phosphorylation (k3) in patients with AD compared to healthy
age-matched controls in multiple cortical and subcortical regions
of the brain with the greatest significant difference in the parietal
and temporal cortex.
Mosconi et al., 2007b Dynamic FDG-PET study with arterial blood sampling in 7 AD
patients and 6 age matched controls and CMRglc was calculated.
AD patients showed significant CMRglc reductions in the
hippocampus and posterior cingulate cortex.
K1 was reduced in the hippocampus and k3 was reduced in the
hippocampus, PCC and amygdala.
Gejl et al., 2017 FDG-PET study as part of a randomized control trial using 6 month
treatment of GLP-1 analog or placebo in AD subjects, measuring
blood-brain glucose transfer capacity (Tmax) and cerebral
metabolic rate of glucose (CMRglc) in the AD patients and controls.
CMRglc estimates were positively correlated with cognition while
Tmax and CMRglc estimates were inversely correlated with AD
duration.
GLP-1 analog treatment significantly raised Tmax estimates of
cerebral cortex from 0.72 to 1.1 umol/g/min, matching Tmax
estimates in healthy volunteers.
but not significantly reduced in either T2DM or T2DM-AD
groups. GLUT3 was significantly reduced in all three groups
with the lowest levels in T2DM brain. Interestingly, GLUT2 was
significantly increased in the AD brain and brains of subjects with
both AD and T2DM, possibly due to astrocyte overactivation (Liu
et al., 2009). Harr et al. (1995) observed reductions in GLUT3
levels in the outer portion of the molecular layer of the dentate
gyrus in AD brains.
A small number of studies have investigated the link between
glucose transporters and AD pathologies in human tissue.
Kawai et al. (1990) investigated the relationship between Aβ
plaques and capillary glucose transporter density. Capillary
glucose transporter density was reduced within Aβ plaques but
increased in the immediate surroundings of Aβ plaques. Liu
et al. (2008) found decreased levels of GLUT1 and GLUT3 in
hippocampus and entorhinal cortex of AD brain tissue correlated
with hyperphosphorylation of tau and NFT density. A recent
study using participants from the Baltimore Longitudinal Study
of Aging cohort measured GLUT1 and GLUT3 levels in the
middle frontal gyrus of 14 participants with AD, 14 controls,
and 15 with asymptomatic AD pathology, i.e., participants who
exhibited significant AD pathology at post-mortem (including
Aβ plaques, NFTs, and neuropil threads) but without evidence
of cognitive dysfunction as assessed shortly before death. GLUT3
levels were significantly lower in both AD and asymptomatic
AD groups relative to controls, before and after adjusting for
sex, age at death, and neuronal nuclear protein levels. Lower
levels of GLUT3 correlated with the severity of both Aβ and NFT
pathology (An et al., 2018). GLUT1 levels were not significantly
different in any of the groups.
Pujol-Gimenez et al. (2014) and Wang et al. (2012)
investigated glucose transporters other than GLUT1, GLUT2,
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TABLE 3 | A summary of results from rodent post-mortem and tracer studies.
References Methods Findings
Ding et al., 2013 Longitudinal immunohistochemical and imaging study
investigating hippocampal GLUT1, GLUT3, and GLUT4, glucose
transport into the brain in female 3xTgAD mice (aged between 3
and 15 months).
Both 3xTgAD and wild-types underwent significant age-related
reductions in glucose transport as detected using FDG-microPET,
beginning at 6-9 months of age, but mechanisms were different.
Reductions in GLUT1 (55 kDa isoform), increases in GLUT1 (45
kDa) and reductions in GLUT3 were observed in 3xTgAD mice,
and non-monotonic changes in GLUT1 (55 kDa), decreases in
GLUT3, and increases in membrane GLUT4 were observed in
wild-types.
Do et al., 2014 Immunohistochemistry study investigating hippocampal GLUT1
expression in 3xTgAD mice aged between 3 and 18 months and
APP/PS1 mice aged 8 months. Vascular volume fraction and
uptake of D-glucose were measured using radionuclide-based
brain perfusion tracers.
GLUT1 expression and D-glucose uptake were reduced in 18
month old 3xTgAD mice, but no differences were found in glucose
transport or GLUT1 in either strain at 8 months. Reduced vascular
volume fractions were observed at 6 months in 3xTg mice and in 8
month old APP/PS1 mice.
Griffith et al., 2019 Longitudinal analysis of 3xTg mice studied at ages 1–3, 6–8, and
16–18 months. Glucose tolerance was assessed alongside
Western blot analysis of hippocampal insulin pathways PI3K/AKT
and MAPK/ERK, and glucose transporters GLUT3 and GLUT4.
GLUT1 was not studied.
Glucose tolerance and plasma insulin levels were found to be
reduced as early as 1 month, well before detection of plaques (14
months). GLUT3 reductions but not GLUT4 were observed later at
18–20 months.
Hooijmans et al., 2007 Immunohistochemistry study into the causal relationship between
GLUT1 reductions in the hippocampus and cortex and Aβ.
Computer-assisted analysis of capillary density, and Aβ in young (8
months) and old (18 months) APP/PS1 mice. GLUT1 expression
was normalized to capillary density to correct for potential loss of
vascular volume.
At 8 months, GLUT1, capillary density or GLUT1 amount per
capillary density were not different between APP/PS1 and
wild-types. At 18 months, GLUT1 was reduced in the
hippocampus of 18 month APP/PS1 mice relative to wild-types,
while capillary density was not significantly different. The ratio of
GLUT1 amount per capillary density was decreased in the dendate
gyrus only. Aging produced significant reductions in GLUT1 and
capillary density, but the ratio of GLUT1 amount per density was
unchanged with age. No cortical changes were observed.
Kouznetsova et al.,
2006
Immunohistochemistry study of Tg2576 mice aged 4–18 months
to stain cortical GLUT1 and Aβ plaques and to assess impact of
size and load of Aβ plaques on GLUT1 expression.
GLUT1 was reduced in cortical regions with high plaque load was
associated with greater reductions compared to areas with low
plaque load. Around large plaques, the capillary density was lower
than around diffuse smaller plaques.
Kuznetsova and
Schliebs, 2013
Immunohistochemistry study investigating GLUT1 and Aβ in
somatosensory cortex of Tg2576 mice aged between 4 and 18
months.
No changes in GLUT1 at 10 months, when plaque deposition is
beginning, but reductions found in 18 month mice when plaque
load is considerable indicating Aβ may contribute to reductions in
GLUT1.
Gil-Iturbe et al., 2020 Western blot study investigating GLUT1, GLUT3, GLUT4, and
GLUT12 in the frontal cortex of two amyloidogenic mouse models
Tg2576 (16 months old) and APP/PS1 (16 months old). Age
effects assessed in C57/6/SJL wild-type mice aged 2–3 and 18
months old. To assess effects of Aβ directly, Aβ1–42 was injected
intra-cerebroventricularly in 3 month old C47BL/6J mice.
Tg2576 and APP/PS1 mice exhibited decreased GLUT1 and
GLUT3 and increased GLUT12. No changes were found in
GLUT4. No age-dependent effects were found in GLUT1 and
GLUT3 in C57/6/SJL mice. In Aβ1–42 injected mice, the same
patterns in up- and downregulation of GLUTs were observed
indicating a direct link between GLUTs and amyloid toxicity.
Merlini et al., 2011 Immunohistochemistry study into the morphology, biochemistry
and functionality of cortical and hippocampal blood vessels in
arcAβ mice at 6, 9–12, and 16–22 months. GLUT1 and GLUT3
measured by immunoblot, corrected for vascular volume using
CD31. Brain glucose levels dynamically measured following i.v.
administration of glucose using microdialysis.
Reductions in BBB and astrocytic GLUT1, but not GLUT3,
reduced from mid-stage pathology onwards. Glucose uptake as
measured using microdialysis confirmed reduced glucose
transport. IgG extravasation observed at late-stages.
Ahn et al., 2018 Immunohistochemistry study investigating GLUT1 and tight
junction protein ZO-1 expression in 4.5 and 9 month old 5xFAD
mice.
Reductions in GLUT1 and ZO-1 observed in the hippocampus and
cortex at both ages, which got worse with age and correlated with
worsening of astrocyte activation (GFAP) and amyloid deposition.
Shang et al., 2019 Immunohistochemistry study assessing the impact of chronic
cerebral hypo-perfusion (CCH) and AD pathology on cortical
GLUT1 expression in 12 month old APP23 mice.
GLUT1 was reduced in cortex of APP23 mice compared to
wild-types, which was further reduced in APP23 mice subject to
CCH, indicating that AD and cerebrovascular pathologies may
interact to exacerbate GLUT1 changes.
Lee et al., 2013 Western blot study of whole-brain expression of GLUT1, GLUT3,
and GLUT4 and insulin markers in 12 month old NSE/hPS2m
mice.
Reductions in GLUT1 and GLUT3, but not GLUT4 observed.
Blood glucose found to be higher in AD mice.
(Continued)
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TABLE 3 | Continued
References Methods Findings
Chua et al., 2012 Longitudinal western blot study of GLUT3 and GLUT4
AβPPsw/PS11E9 mice
Reduced brain glucose and insulin content in 12 and 15 month
old brains accompanied by increased GLUT3 and GLUT4, which
preceded significant upregulation of Aβ42 in brain. GLUT1 not
measured.
Deng et al., 2009 Western blotting study of insulin signaling and glucose
transporters in intracerebroventricular streptozotocin (STZ) rat
model of AD (6 months old, 21 days after STZ injections).
Reduced GLUT1 and GLUT3 in the cerebrum, and reduced
GLUT3 in the cerebellum. Reduced pERK1 and pPI3K,
pGSK-3β(S9) markers, and increased phosphorylation of tau.
Salkovic-Petrisic et al.,
2014
Study investigating effect of long-term galactose administration on
brain metabolism and glucose transporters via Western blot in
intra-cerebroventricular streptozotocin (STZ) rat model of AD.
Adult rats were used, and galactose administered for 1 month.
STZ rat exhibited significantly reduced GLUT3 expression in the
hippocampus, which was normalized with galactose
administration.
Knezovic et al., 2017 Western blot study investigating expression of GLUT2, insulin
receptor, and neuroinflammatory marker GFAP in the
hippocampus and cortex in intra-cerebroventricular streptozotocin
(STZ) rat model of AD (adult males). Measurements were taken 1 h
after STZ administration.
GLUT2 increased in the hippocampus, but unchanged in cortical
regions. Insulin receptor decreased in parietal and temporal
cortex, but not the hippocampus.
Biswas et al., 2018 Western blot and immunohistochemistry study investigating the
expression of cortical and hippocampal GLUT1 and GLUT3, and
brain glucose levels in intra-cerebroventricular streptozotocin (STZ)
rat model of AD (adult males), and correlation with markers of
endoplasmic reticulum stress, and astrocyte/microglia activation
(Cd11b).
Glucose transporters GLUT1 and GLUT3 and brain glucose
concentration were reduced in STZ rats. These changes were
accompanied by reduced mitochondrial activity, increased
endoplasmic reticulum stress, and increased microglial activation.
FIGURE 2 | PRISMA diagram.
and GLUT3. Pujol-Gimenez et al. (2014) identified that the
expression of GLUT12, a newly discovered glucose transporter
found primarily in insulin-sensitive tissues (Stuart et al., 2009),
was significantly increased in the frontal cortices of AD subjects
compared to age-matched controls. Wang et al. (2012) examined
the role of SLC2A14, the gene encoding GLUT14, in blood
samples of patients with developing late onset AD. They
performed a case-control study in a Chinese population of
597 patients with AD and 605 healthy controls, showing that
SLC2A14 polymorphisms appear to confer increased risk of
developing AD.
Alterations in GLUTs have also been observed in rodent
models of AD. In a longitudinal study of 3xTgAD mice between
3 and 15 months of age, glucose transporters GLUT1 (55 and 45
kDa), and GLUT3 were found to change in both AD and wild-
type animals but with differing temporal trajectories (Ding et al.,
2013). In AD mice, GLUT1 (55 kDa) and GLUT3 were found
to decrease with age, whereas GLUT1 (45 kDa) was found to
increase with age. In wild-types, non-monotonic changes with
age were observed for GLUT1 (55 kDa), whereas GLUT1 (45
kDa) was unchanged. GLUT3 decreased, and GLUT4 increased
with age. Unfortunately, a formal comparison between glucose
transporter expression between 3xTgAD mice and wild-types
was not performed. In another longitudinal study, Do et al.
(2014) studied vascular volume fraction and GLUT1 expression
in the hippocampus of 3xTgAD and APP/PS1 mice and found
no change in GLUT1 compared to wild-types at 8 months, but
significantly reduced GLUT1 expression in 3xTgAD mice at
18 months after substantial amyloid-pathology had developed.
APP/PS1 mice were not studied at this later timepoint. Griffith
et al. (2019) investigated GLUT3 and GLUT4, but not GLUT1,
longitudinally in 3xTg mice. They found similar timing of effects
on GLUT3 as observed for GLUT1 by Do et al. (2014). Young
rats exhibited reduced glucose tolerance (as early as 1 month),
but GLUT3 did not change relative to wild-types until at least
18–20 months. GLUT4 was unaltered at all ages. Similar results
were found in other AD models. Hooijmans et al. (2007) did
not find any changes in GLUT1 expression between APP/PS1
mice and wild-types at 8 months, but found significantly reduced
total GLUT1, reduced capillary density, and reduced GLUT1 per
vascular volume fraction in 18 month old mice. Changes were
found in the hippocampus, but not the cortex. In the Tg2576
model, Kuznetsova and Schliebs (2013) showed that cortical
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GLUT1 was unaltered at 10 months compared to wild-types, but
at 18 months after development of amyloid pathology, AD mice
had significantly lower cortical GLUT1.
A study by Kouznetsova et al. (2006) aimed to investigate if
the degree of GLUT1 changes were related to amyloid load. In
cortical regions with high amyloid load, GLUT1 staining was
reduced compared to regions with low amyloid load. The authors
also showed that GLUT1 staining was reduced nearer large senile
plaques, relative to changes observed near smaller diffuse plaques.
Gil-Iturbe et al. (2020) performed a more thorough investigation
of GLUTs,measuring expression of GLUT1, GLUT3, GLUT4, and
GLUT12 in two amyloidogenic models (Tg2576 and APP/PS1)
aged 16 months old. They also investigated effects of aging
in C57/6/SJL mice and the effects of amyloid on GLUTs via
intracerebral injection of Aβ1−42. The authors found reduced
GLUT1 and GLUT3, and increased GLUT12 in both strains. No
age dependent effects on GLUTs were observed, conflicting with
results from Ding et al. (2013). Injection of Aβ1−42 produced
similar reductions in GLUT1 and GLUT3 as found in the Tg2576
and APP/PS1 mice, indicating a direct link between GLUT1
decreases and amyloid. Merlini et al. (2011) investigated GLUT
changes in the arcAβ model. They observed reductions in BBB
and astrocytic GLUT1 in the cortex and hippocampus from 9
to 12 months onward, which coincided with changes in glucose
uptake as measured using microdialysis. However, GLUT3 was
unaltered. By 16–22 months, IgG extravasation was observed,
indicating loss of BBB integrity. In 5xFAD aged 4.5 and 9months,
reductions in GLUT1 and tight junction protein ZO-1 were
found at both timepoints (Ahn et al., 2018). GLUT3 was not
studied. Another study in 12 month old NSE/hPS2m mice also
showed reductions in GLUT1 and GLUT3, but not GLUT4 (Lee
et al., 2013). A study by Chua et al. (2012) in AβPPsw/PS11E9
mice did not agree with changes observed in other models. Brain
glucose levels were measured to be lower than wildtypes at 12
and 15 months of age, but GLUT3 and GLUT4 were found to
be upregulated, not decreased (Chua et al., 2012). Unfortunately,
changes to GLUT1 were not studied.
Shang et al. (2019) investigated the additional effects of
chronic cerebral hypoperfusion on GLUT1 expression in APP23
mice. In normal APP23 mice, GLUT1 reductions were observed
at 12 months, which were further reduced in APP23 mice with
chronic cerebral hypoperfusion (Shang et al., 2019).
A number of studies have investigated GLUT expression in a
rat model of AD produced by administering streptozotocin via
intracerebroventricular injection. These studies found reduced
expression of GLUT1 (Deng et al., 2009; Biswas et al., 2018),
reduced expression of GLUT3 (Deng et al., 2009; Salkovic-
Petrisic et al., 2014; Biswas et al., 2018), and increased expression
of GLUT2 (Knezovic et al., 2017).
Evidence of Altered Glucose Transport in
AD From in-vivo Tracer Studies
Friedland et al. (1989) used FDG-PET to measure cerebral
transport and phosphorylation rates of glucose in patients with
probable AD and healthy age-matched controls. No difference in
the transport rate constants, K1 and k2, or the utilization rate k3,
were observed between groups. Two later FDG-PET studies in
AD patients showed different results; Jagust et al. (1991) showed
a reduction in the transport rate constant K1 in the frontal and
temporal cortex with minimal differences in occipital cortex and
total brain white matter, and a reduction in regional CMRglu
in all cortical regions compared to controls; Piert et al. (1996)
found significant reductions in K1 and k3 in multiple cortical
and subcortical regions of the brain in people with AD compared
to controls with the most significant reductions being seen in
the parietal and temporal cortices. Kimura and Naganawa (2005)
performed dynamic PET studies in three subjects, a 45-year-
old normal subject, a 65-year-old subject with mild AD, and
a 70-year-old subject with severe AD. Glucose transport was
globally reduced in both AD cases compared to the normal
subject. Glucose phosphorylation was diminished in gray matter
of the severe case of AD, excluding the sensory, motor, and
visual cortices. In the mild case, phosphorylation was reduced
in the right parieto-temporal area. In another dynamic FDG-
PET study of seven patients with mild AD and six normal age-
matched controls, Mosconi et al. (2007b) showed significant
reductions in K1 in the hippocampus in AD compared to
controls, although relative CMRglu was better able to identify
AD from controls, likely due to the additional contribution of
reduced glucose phosphorylation.
A small number of tracer studies have been performed in
rodents, which all support reduced transport of glucose in AD.
Do et al. (2014) perfused brains of 3xTgAD and wild-type
mice with [3H]-D-glucose (0.3 mCi/ml) immediately prior to
decapitation and measurement of tissue radioactivity using a
scintillation counter (Do et al., 2014). No difference in [3H]-D-
glucose uptake was found in 3xTgAD mice compared to wild-
types aged 6 or 8 months, but a significant decrease was found
in 3xTgAD mice at 18 months. The reduced uptake at 18 month
was associated with reduced expression of GLUT1 at the same
timepoint. Ding et al. (2013) used micro-FDG-PET to study
glucose uptake in 3xTgAD mice and wild-types at various ages.
FDG-PET signals were measured at 40min post injection of
FDG, and are likely to reflect both transport and utilization.
Reductions in the FDG-PET signal were found in both AD and
wild-type animals with age, but while no formal comparison
was made, FDG-PET signals did not appear to differ across
genotype. Last, Merlini et al. (2011) performed microdialysis
in arcAβ following intravenous injection of glucose and found
reduced uptake compared to wild-types, despite increases in IgG
extravasation in AD mice.
Effects of GLUT Alterations on Brain
Physiology
The effects of GLUT disruptions on the brain have been studied
in rodent models. Abdul Muneer et al. (2011) induced GLUT1
disruption in a mouse model through the administration of
methamphetamine. This led to a reduction in BBB tight junction
proteins, indicating that GLUTs may play a role in regulating
BBB integrity. Winkler et al. (2015) later demonstrated that
GLUT1 deficient mice overexpressing APP showed changes
characteristic of AD. These included reduced brain capillary
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levels of low-density lipoprotein receptor-related protein 1
(LRP1), a transporter at the BBB which clears Aβ from the brain
(Zlokovic, 2008, 2011), diminished cerebral blood flow, early
BBB breakdown, accelerated Aβ deposition in the hippocampus
and cortex, neuronal dysfunction and cognitive impairment.
They also observed that vascular changes preceded neuronal
dysfunction in these mice. Decreased levels of GLUT1 and
GLUT3 were found in a rat model of sporadic AD, achieved
through the intracerebroventricular injection of streptozotocin,
alongside impaired insulin signaling and abnormalities in
phosphorylation and microtubule binding activity of tau (Deng
et al., 2009).
Effects of severe glucose transporter depletion on early brain
development can be observed in human GLUT1 deficiency
syndrome, a rare genetic disorder characterized by impaired
glucose metabolism due to a deficiency in GLUT1. Clinical
features include intellectual disability, movement disorders and
epileptic seizures refractory to treatment. Late-onset GLUT1
deficiency syndrome affects children at an older age, with
evidence showing mild to moderate intellectual disability (Leen
et al., 2010). A later study by the same group followed
up patients with GLUT1 deficiency syndrome between 18
and 41 years old. Their results showed that while the
prominent feature during childhood is epilepsy, this diminishes
later in life and new movement disorders become apparent
during adolescence. Cognitive function, however, did not
appear to worsen with age (Leen et al., 2014). There is
no evidence of GLUT1 deficiency syndrome manifesting in
late adulthood.
Links Between Insulin Resistance and
GLUT Changes
Deficits in transport and metabolism in AD may result from
impaired insulin signaling, particularly due to alterations in the
function of insulin-sensitive transporters. Mullins et al. (2017)
investigated the relationship between the pathological hallmarks
of AD and genes related to insulin resistance by converting
histological and gene expression data into 3D spatial maps. Their
findings showed that GLUT1 was positively correlated, whereas
GLUT4 was negatively correlated, with insulin signaling proteins
(including IRS-1).
In a mouse model of AD, Chua et al. (2012) found that
insulin signaling molecules were increased, alongside increases
in GLUT3 and GLUT4 expression and decreases in brain
insulin and glucose content, and that these changes occurred
earlier than pathological accumulation of Aβ. In the STZ
rat model of AD, increases in GLUT2 were accompanied
by decreases in insulin receptors (Knezovic et al., 2017).
In the same model, Deng et al. (2009) found decreases in
insulin signaling alongside decreases in GLUT1 and GLUT3
(Deng et al., 2009).
Insulin resistance has been targeted as a means to restore
glucose transport by number of groups. In a small randomized
control trial, Gejl et al. (2017) examined the effects of GLP-
1 analog treatment in patients with a clinical diagnosis of
AD. In their study, 18 participants received liraglutide and 20
received placebo in a 26-week period. Their results showed that
treatment with liraglutide significantly raised the average blood-
brain glucose transport capacity estimate (p < 0.0001) from
0.72 to 1.1 (µmol/g/min) compared to placebo, which positiviely
correlated with measures of cognition. Salkovic-Petrisic et al.
(2014) performed long-term dosing of STZ rats with galactose as
an alternative energy source to glucose and found upregulation of
GLUT3 transporters back to levels observed in healthy rats and
improved cognitive deficit.
DISCUSSION
This systematic review examines the evidence for alterations in
glucose transport in AD and the effect of these alterations on the
brain. The majority of studies investigating GLUT1 and GLUT3
suggest that both transporters are reduced in the hippocampus
and cortex of AD brains. Longitudinal rodent studies did not find
changes at early timepoints, but consistently observed reductions
in transporter expression after Aβ pathology had developed,
indicating that Aβ itself may be responsible.
There were fewer studies investigating other GLUTs including
GLUT2, GLUT4, GLUT12, and GLUT14. A rise in GLUT2 in
AD brain tissue was observed by Liu et al. (2009) and Knezovic
et al. (2017). In the study by Liu et al. (2009), GLUT2 changes
were exacerbated in patients who also had T2DM. It is possible
that GLUT2 increases to serve as a compensatory mechanism of
GLUT1 and GLUT3 loss. The role of GLUT2, therefore, requires
further investigation. No changes in GLUT4, an insulin sensitive
transporter, were found in aged NSE/hPS2m (Lee et al., 2013)
or 3xTg mice (Griffith et al., 2019), whereas Chua et al. (2012)
found increases in AβPPsw/PS11E9 mice. Pujol-Gimenez et al.
(2014) showed GLUT12, also an insulin-sensitive transporter,
was increased in AD brain tissue. A study by Purcell et al.
(2011) showed that overexpression of GLUT12 in healthy mice
improved whole-body insulin sensitivity, indicating GLUT12
may play a compensatory role when insulin resistance develops in
AD. The findings by Wang et al. (2012) on GLUT14 demonstrate
that SLC2A14 polymorphisms may increase susceptibility to
late-onset AD. Further work is required to determine the
role of these lesser-studied GLUTs in AD and gauge their
therapeutic potential.
The cause of glucose transporter expression in AD remains
unclear. One suggestion for the reduction of GLUT1 in the
AD brain is an abnormality in the translation process of the
transporter. Brains of AD patients have been found to express
low levels of transcription factor hypoxia-inducible factor 1α, a
protein complex which regulates GLUT1 and GLUT3 expression
(Liu et al., 2008; Cohen et al., 2014). However, Mooradian
et al. (1997) did not observe any changes in GLUT1 mRNA
concentrations, which suggests a post-translational abnormality.
Another study proposed that the activation of calpain I, a
calcium sensitive protease, is a potential cause of GLUT3
under-expression (Jin et al., 2013) due to its damaging effect
through proteolysis of GLUT3 promoters. Calpain I has also
been associated with downregulation of protective mechanisms
against tau phosphorylation (Gu et al., 2018).
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AD pathologies such as Aβ or tau may directly reduce
GLUT expression. The low capillary density found within Aβ
plaques in the study by Kawai et al. (1990) may suggest that
Aβ plaques lead to the degeneration of capillaries, which may
in turn affect GLUT expression. Findings by An et al. (2018)
suggest that a reduction of GLUT3 but not GLUT1 is more
closely correlated with Aβ and NFT abnormalities. Studies using
amyloidogenic mouse models support a link between spatial
proximity of Aβ to glucose transporter alterations (Kouznetsova
et al., 2006; Kuznetsova and Schliebs, 2013), and indicate
that GLUT changes occur after development of Aβ pathology
(Hooijmans et al., 2007; Kuznetsova and Schliebs, 2013; Do
et al., 2014; Griffith et al., 2019). Injection of Aβ1−42 into the
brain of healthy mice produced very similar effects on GLUT
expression as observed in AD mice, indicating Aβ plays a direct
role in modulating GLUT expression (Gil-Iturbe et al., 2020).
Mark et al. (1997) examined the relationship between Aβ and
glucose transport, by examining cultured rat hippocampal and
cortical neurons. Their results demonstrate that Aβ deposition
impairs glucose transport through a mechanism involving
membrane lipid peroxidation. The authors suggest that this
mechanism may further lead to neurodegeneration in AD.
In a drosophila study, Niccoli et al. (2016) demonstrated a
protective effect against Aβ toxicity by genetically upregulating
glucose transporters. Similar results were demonstrated when
using metformin, an anti-diabetic drug designed to stimulate
glucose uptake into cells. Human studies are yet to confirm
these findings.
Without measuring glucose uptake into brain tissue, it is
difficult to know how changes in GLUTs affect glucose availability
in parenchymal cells. Tracer studies that measure uptake of
glucose and glucose-analogs into brain are therefore crucial
for determining the impact of GLUT changes on glucose
transport. Uptake of glucose can be measured using a range
of methods from invasive perfusion-based approaches, to non-
invasive imaging techniques such as FDG-PET. Generally, tracer-
based studies performed to date show that transport of glucose
into the brains of AD patients and rodent models of AD is
reduced. Unfortunately, these studies cannot distinguish between
glucose transport through the BBB or through cell membranes.
The affinity of glucose for GLUT3 (Kt = 1.4mM, measured using
2DG) is much higher than that of GLUT1 (Kt = 6.9mM, also
measured using 2DG; lower Kt values relate to higher affinity),
and therefore glucose transport across the BBB is likely to be
rate limiting under most conditions (Simpson et al., 2008).
Furthermore, Lund-Andersen (1979) and Pardridge (1994) argue
that because the total surface area and mass of GLUTs on
parenchymal cells far exceeds that of endothelial cells, glucose
uptake into the intracellular space is limited by GLUT1 at the
BBB, not by astrocyte GLUT1 or neuronal GLUT3. Therefore,
it is likely that reductions in uptake of glucose or glucose-
analogs into brain tissue reflect mainly reductions to GLUT1
at the BBB.
GLUT1 and GLUT3 are considered insulin-independent
glucose transporters, and therefore are assumed not to be
affected by insulin or insulin-like growth factors. It is therefore
expected that insulin-resistance does not alter uptake of glucose
through these transporters. However, there is some evidence
that GLUT1 and GLUT3 may be moderately affected by
insulin. Hernandez-Garzón et al. (2016) observed that astrocytic
insulin-like growth factor receptor modulates the expression
of GLUT1, but the authors did not determine if this affected
uptake of glucose. Muhič et al. (2015) did not observe any
effects of insulin or insulin growth factor on glucose uptake
into astrocytes, suggesting that GLUT1, and even the insulin-
sensitive transporter GLUT4 present on astrocytes, are not
particularly sensitive to insulin. The effects of insulin on
endothelial GLUT1 has not been studied. Hypoglycemia is
known to cause upregulation of BBB GLUT1 and neuronal
GLUT3, an adaptive mechanism to ensure sufficient glucose is
delivered to the brain (Kumagai et al., 1995; Simpson et al.,
1999; Yun et al., 2018). It is possible these changes occur
due to hyperinsulinemia—a study in man showed that insulin
increases uptake of glucose across the BBB, however the dose
of insulin required to detect an effect was non-physiological.
It is likely the dominant driver of GLUT1 changes at the BBB
is glucose itself; in-vitro studies show hyperglycemia increases
GLUT1 and glucose uptake in the absence of insulin (Takakura
et al., 1991; Sajja et al., 2014). Despite this, the studies of
Deng et al. (2009), Chua et al. (2012), and Mullins et al.
(2017) support an association between insulin resistance and
altered expression of insulin-insensitive transporters GLUT1
and GLUT3.
It is possible the link between insulin resistance and alterations
to insulin-insensitive GLUTs occurs via a joint relationship with
AD pathologies Aβ and tau. Mullins et al. (2017) found areas
exhibiting lower expression of glucose transporters and insulin
signaling genes had higher levels of Aβ and tau pathology.
Insulin is known to promote Aβ clearance (Watson et al., 2003)
while insulin resistance promotes the formation of Aβ oligomers
(Yamamoto et al., 2012). It is suggested that a positive feedback
loop subsequently occurs as Aβ oligomers lead to increased
phosphorylation of insulin signaling proteins (Yoon et al., 2012)
which, in turn, leads to further insulin resistance. The results
from the randomized controlled trial on the use of liraglutide in
AD provides further insight into the possible link between insulin
resistance, glucose transporters and AD (Gejl et al., 2016). Their
results show an improvement in glucose transport capacity with
liraglutide. It is not clear whether this improvement reflects an
increase in glucose transporters or an increase in postprandial
insulin levels, however, as liraglutide does not cross the BBB, it
is possible that it causes a direct effect on the BBB itself.
CLINICAL SIGNIFICANCE AND FUTURE
PERSPECTIVE
Altered glucose metabolism occurs several years before evidence
of cognitive impairment in AD (Chen and Zhong, 2013).
Altered glucose transport has also been observed in mild
cognitive impairment (MCI) (Mosconi et al., 2013), and deletion
of glucose transporters has been shown to cause substantial
neurodegenerative effects in animal models (Nicholson et al.,
2010; Ding et al., 2013; Winkler et al., 2015). This suggests that
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drugs targeting the restoration of normal GLUT expression may
be highly effective at reducing cognitive decline and transition
from MCI to AD. Only a small proportion of drugs are able
to cross the BBB, mainly due to the characteristic properties
of desolvation, lipophilicity, molecular volume and dipole
moment required for molecules to cross the BBB (Fong, 2015).
Additionally, the BBB has tight control over what molecules
leave the brain, making drug development in neurodegenerative
disease more challenging (Pardridge, 2009). GLUT1 therefore
becomes a highly attractive therapeutic target since it is present
on the BBB itself.
GLUTs play a significant role in AD pathology with
substantial evidence suggesting that GLUT1 and GLUT3
reductions occur following amyloid accumulation, but may
precede the onset of clinical symptoms, while GLUT2 and
GLUT12 appear to increase and may have a compensatory
role. FDG-PET imaging could provide a means to detect
reduced glucose transport in a clinical setting. Repurposing
anti-diabetic drugs shows promising results in human studies
of AD (Gejl et al., 2016, 2017). With evidence suggesting that
metabolic changes can accurately predict subsequent cognitive
decline (De Leon et al., 2001; Jagust et al., 2006; Mosconi
et al., 2008), therapeutic strategies aiming to modify glucose
transport could have a significant impact in clinical management
of AD.
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